Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Circulating tumor DNA testing in advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 May 2018

Moding Everett J, Diehn Maximilian, Wakelee Heather A

Abstract excerpt

Circulating tumor DNA (ctDNA) shed from cancer cells into the peripheral blood can be non-invasively collected and tested for the presence of tumor-specific mutations. Mutations identified in ctDNA can predict responses to targeted therapies and emerging evidence suggests that changes in ctDNA levels over time can be used to monitor response to therapy and detect disease recurrence. Given the emergence of...

Topics

Animals
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Pharmacological
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Circulating Tumor DNA
ErbB Receptors
Humans
Lung Neoplasms
Mutation
Neoplasm Staging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Prognosis

Source

Identifiers

PMID: 29656751
DOI: 10.1016/j.lungcan.2018.02.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA testing in advanced non-small cell lung cancer.PMID 29656751Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.Semantic proximity Read ↗

Role of circulating-tumor DNA analysis in non-small cell lung cancer.Semantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.